<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110118</url>
  </required_header>
  <id_info>
    <org_study_id>LY01008/CT-CHN-103</org_study_id>
    <nct_id>NCT05110118</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Single-dose, Parallel-group Study Comparing Pharmacokinetic Characteristics, Safety , Tolerability and Immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Boan Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Boan Biotechnology Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, single-dose, parallel-group study comparing&#xD;
      pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008&#xD;
      (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody&#xD;
      Injection) and Avastin (Bevacizumab Injection) in healthy Chinese male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last measurable concentration（AUC0-t）</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity（AUC0-∞）</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum (peak) plasma concentration（Cmax）</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Chloride（CL）</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life（t1/2）</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution（Vd）</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events(AEs)</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECGs</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of serum anti-drug antibody (ADA)</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of neutralizing antibody (NAb)</measure>
    <time_frame>From baseline to Day 99</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <condition>Non Small Cell Lung Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>LY01008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of LY01008 3 mg/kg for 90 min(±1 min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intravenous injection of Avastin 3 mg/kg for 90 min(±1 min).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY01008</intervention_name>
    <description>Single intravenous injection</description>
    <arm_group_label>LY01008</arm_group_label>
    <other_name>Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Single intravenous injection</description>
    <arm_group_label>Avastin</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers&#xD;
&#xD;
          -  Subjects aged 18 - 45 years&#xD;
&#xD;
          -  Subjects weighing ≥ 50.0 kg and ≤ 100.0 kg&#xD;
&#xD;
          -  Subjects with a body mass index (BMI) ≥ 19.0 and ≤ 26.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with evidence or history of clinically significant disease&#xD;
&#xD;
          -  Subjects with a history of previous cancer&#xD;
&#xD;
          -  Subjects with a history of hypertension, or abnormal blood pressure at&#xD;
             screening/baseline measurements (systolic blood pressure &gt; 140 mmHg and/or diastolic&#xD;
             blood pressure &gt; 90 mmHg confirmed by a repeat measurement on the same day)&#xD;
&#xD;
          -  Subjects with a history of blood donation 3 months before study drug infusion&#xD;
&#xD;
          -  Subjects with a history of exposure to antibodies 12 months before study drug infusion&#xD;
&#xD;
          -  Subjects with previous exposure to anti-VEGF therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

